SCHEMBL1036596

SCHEMBL1036596

O=C(O)COCCCCN1C(=O)CCC1CC[C@@H](O)Cc1cccc(Cl)c1

nearest known ligand 0.79

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
PTGER3 P43115 2/20 0.61
PTGER4 P35408 1/20 0.61
PTGER2 P43116 1/20 0.61
PTGER1 P34995 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1035091 1.00 PTGER3 (0.61) PTGER3PTGER4PTGER2PTGER1
SCHEMBL1036597 1.00 PTGER3 (0.61) PTGER3PTGER4PTGER2PTGER1
SCHEMBL1036209 0.91 PTGER3 (0.54) PTGER3PTGER4PTGER2PTGER1
SCHEMBL1036208 0.91 PTGER3 (0.54) PTGER3PTGER4PTGER2PTGER1
SCHEMBL1036210 0.91 PTGER3 (0.54) PTGER3PTGER4PTGER2PTGER1
SCHEMBL6164622 0.88 PTGER4 (0.76) PTGER3PTGER4PTGER2
SCHEMBL6164617 0.88 PTGER4 (0.76) PTGER3PTGER4PTGER2
SCHEMBL5682236 0.86 PTGER3 (0.60) PTGER3PTGER4PTGER2PTGER1
SCHEMBL1378106 0.84 PTGER3 (0.54) PTGER3PTGER4PTGER2PTGER1
SCHEMBL1378110 0.84 PTGER3 (0.54) PTGER3PTGER4PTGER2PTGER1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1638936-B1 3-OXA-8-AZAPROSTAGLANDIN ANALOGS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE ALLERGAN INC (US) 2011-01-26 EP claimed
US-6734206-B1 POTENT OCULAR HYPOTENSIVES THAT ARE PARTICULARLY SUITED FOR THE MANAGEMENT OF GLAUCOMA ALLERGAN, INC. 2004-05-11 US claimed
EP-1638936-B1 3-OXA-8-AZAPROSTAGLANDIN ANALOGS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE ALLERGAN INC (US) 2011-01-26 EP disclosed
US-6734206-B1 POTENT OCULAR HYPOTENSIVES THAT ARE PARTICULARLY SUITED FOR THE MANAGEMENT OF GLAUCOMA ALLERGAN, INC. 2004-05-11 US disclosed